Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501770 | 1.00 | OPRL1 (0.70) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6471908 | 0.89 | OPRL1 (0.55) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6471905 | 0.89 | OPRL1 (0.55) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6501020 | 0.87 | OPRL1 (0.59) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6501015 | 0.87 | OPRL1 (0.59) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6469083 | 0.85 | OPRM1 (0.55) | OPRL1OPRM1KCNH2HDAC1HDAC6 | |
| SCHEMBL6471078 | 0.83 | OPRL1 (1.00) | OPRL1OPRM1KCNH2SIGMAR1 | |
| SCHEMBL6471157 | 0.83 | OPRL1 (0.62) | OPRL1OPRM1KCNH2 | |
| SCHEMBL6471651 | 0.78 | OPRL1 (0.48) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 | |
| SCHEMBL6471648 | 0.78 | OPRL1 (0.48) | OPRL1OPRM1KCNH2SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005009970-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GATIFLOXACIN | MATRIX LABORATORIES LTD (IN) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | OPRL1 1/4885OPRM1 8/4885KCNH2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.